Alessandro Serafini

Alessandro Serafini


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in European Radiology
Verified
Journal Article
Open access
PDF file
MGMarco Gatti
Marco Gatti
RFRiccardo Faletti
Riccardo Faletti
FGFrancesco Gentile
Francesco Gentile
ESEnrico Soncin
Enrico Soncin
GCGiorgio Calleris
Giorgio Calleris
PFPaolo Fonio
Paolo Fonio
Objective: To investigate the diagnostic accuracy of the PI-RADS v2.1 multiparametric magnetic resonance imaging (mpMRI) features in predicting extraprostatic extension (mEPE) of prostate cancer (PCa), as well as to develop and validate a comprehensive mpMRI-derived score (mEPE-score). Methods: We retrospectively reviewed all consecutive patients admitted to two institutions for radical prostatectomy for PCa with available records of mpMRI performed between January 2015 and December 2020. Data from one institution was used for investigating diagnostic performance of each mEPE feature using radical prostatectomy specimens as benchmark. The results were implemented in a mEPE-score as follows: no mEPE features: 1; capsular abutment: 2; irregular or spiculated margin: 3; bulging prostatic contour, or asymmetry of the neurovascular bundles, or tumor-capsule interface > 1.0 cm: 4; ≥ 2 of the previous three parameters or measurable extraprostatic disease: 5. The performance of mEPE features was evaluated using the five diagnostic parameters and ROC curve analysis. Results: Two-hundred patients were enrolled at site 1 and 76 at site 2. mEPE features had poor sensitivities ranging from 0.08 (0.00–0.15) to 0.71 (0.59–0.83), whereas specificity ranged from 0.68 (0.58–0.79) to 1.00. mEPE-score showed excellent discriminating ability (AUC > 0.8) and sensitivity = 0.82 and specificity = 0.77 with a threshold of 3. mEPE-score had AUC comparable to ESUR-score (p = 0.59 internal validation; p = 0.82 external validation), higher than or comparable to mEPE-grade (p = 0.04 internal validation; p = 0.58 external validation), and higher than early-and-late-EPE (p < 0.0001 internal and external validation). There were no significant differences between readers having different expertise with EPE-score (p = 0.32) or mEPE-grade (p = 0.45), but there were significant differences for ESUR-score (p = 0.02) and early-versus-late-EPE (p = 0.03). Conclusions: The individual mEPE features have low sensitivity and high specificity. The use of mEPE-score allows for consistent and reliable assessment for pathologic EPE. Key Points: • Individual PI-RADS v2.1 mpMRI features had poor sensitivities ranging from 0.08 (0.00–0.15) to 0.71 (0.59–0.83), whereas Sp ranged from 0.68 (0.58–0.79) to 1.00. • mEPE-score is an all-inclusive score for the assessment of pEPE with excellent discriminating ability (i.e., AUC > 0.8) and Se = 0.82, Sp = 0.77, PPV = 0.74, and NPV = 0.84 with a threshold of 3. • The diagnostic performance of the expert reader and beginner reader with pEPE-score was comparable (p = 0.32).

1 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GIULIA NICOLETTIGIULIA NICOLETTI
GIULIA NICOLETTI
SMSimone Mazzetti
Simone Mazzetti
GMGiovanni Maimone
Giovanni Maimone
VCValentina Cignini
Valentina Cignini
Renato CuocoloRenato Cuocolo
Renato Cuocolo
Valentina GianniniValentina Giannini
Valentina Giannini
In the last years, several studies demonstrated that low-aggressive (Grade Group (GG) ≤ 2) and high-aggressive (GG ≥ 3) prostate cancers (PCas) have different prognoses and mortality. Therefore, the aim of this study was to develop and externally validate a radiomic model to noninvasively classify low-aggressive and high-aggressive PCas based on biparametric magnetic resonance imaging (bpMRI). To this end, 283 patients were retrospectively enrolled from four centers. Features were extracted from apparent diffusion coefficient (ADC) maps and T2-weighted (T2w) sequences. A cross-validation (CV) strategy was adopted to assess the robustness of several classifiers using two out of the four centers. Then, the best classifier was externally validated using the other two centers. An explanation for the final radiomics signature was provided through Shapley additive explanation (SHAP) values and partial dependence plots (PDP). The best combination was a naïve Bayes classifier trained with ten features that reached promising results, i.e., an area under the receiver operating characteristic (ROC) curve (AUC) of 0.75 and 0.73 in the construction and external validation set, respectively. The findings of our work suggest that our radiomics model could help distinguish between low- and high-aggressive PCa. This noninvasive approach, if further validated and integrated into a clinical decision support system able to automatically detect PCa, could help clinicians managing men with suspicion of PCa.

1 July 2021 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
PBPaolo Boretto
Paolo Boretto
ADAlessandro Depaoli
Alessandro Depaoli
FCFederico Conrotto
Federico Conrotto
POPierluigi Omedè
Pierluigi Omedè
OFOvidio De Filippo
Ovidio De Filippo
Fabrizio D'AscenzoFabrizio D'Ascenzo
Fabrizio D'Ascenzo

7 July 2026 in La radiologia medica
Verified
Journal Article
Open access
PDF file
VGVincenza Granata
Vincenza Granata
ASAlessandro Serafini
Alessandro Serafini
RFRoberta Fusco
Roberta Fusco
DCDamiano Caruso
Damiano Caruso
GDGinevra Danti
Ginevra Danti
NGNicoletta Gandolfo
Nicoletta Gandolfo
Background Multidisciplinary management of oncological patients has improved patient outcomes, responding effectively and efficiently to the patient’s health needs. A critical element remains adequate communication, also between radiologist and oncologist, which promotes correct patient management. The Italian Society of Medical Oncology (AIOM) and the Italian Society of Medical and Interventional Radiology (SIRM) have created a working group of representative members to improve not only communication between the two categories but, above all, to allow each member of the different categories to benefit from guidelines of good clinical practice both for filling out the examination request form than the radiological report, and therefore, also allowing clinicians and radiologists who do not work in reference centers, to correctly manage patients in the various phases of their oncological path. Materials and methods A panel of expert oncologists (AIOM members) and radiologists (SIRM members) was established. Multi-round consensus-building Delphi exercise was performed to create a comprehensive structured report (SR) template and a comprehensive requesting model for computed tomography (CT). The requesting model was divided into six sections: (a) oncological family history; (b) relevant clinical data; (c) staging; (d) re-staging; (e) other reason; and (f) follow-up. Regarding CT SR, 3 models were proposed: (1) for staging; (2) for treatment evaluation, and (3) for follow-up. CT SR in staging phase was divided into nine sections: (a) primary tumor; (b) lymph node metastases; (c) liver metastases; (d) lung metastases; (e) brain metastases; (f) other organs (incl. skeleton) metastases; (g) peritoneum; (h) incidental findings and complications; and (i) conclusion. CT SR in treatment evaluation phase was divided into ten sections: (a) primary tumor; (b) lymph node metastases; (c) liver metastases; (d) lung metastases; (e) brain metastases; (f) other organs (incl. skeleton) metastases; (g) peritoneum; (h) treatment-related complication; (i) incidental findings; and (l) conclusion. CT SR in follow-up phase was divided into six sections: (a) appearance of lesions; (b) node metastases; (c) liver lesions; (d) peritoneum; (e) incidental findings and complications; and (f) conclusion. Cronbach’s alpha (Cα) correlation coefficient was used to evaluate internal consistency for each item and the quality analysis according to the average inter-item correlation. Each expert expressed individual comments for each specific template section by using a four-point scale (0 = strongly disagree, 1 = slightly disagree, 2 = modestly agree, 3 = strongly agree). Results With regard to the 3 CT SR reports, at the first round, all sections achieved ratings above the “good” level. The staging items showing the highest level of agreement among experts in the first round were lung metastases and incidental findings and complications. For treatment evaluation, the items with the highest agreement were treatment-related complication and incidental findings. For follow-up, the items with the highest agreement were appearance of lesions and incidental findings and complications. At the first round, Cronbach’s alpha (Cα) correlation coefficients were 0.92, 0.95, and 0.90 for staging, re-staging, and follow-up, respectively. At the second round, all sections achieved ratings at the “excellent” level. Regarding requesting model, at first round, all sections received an overall score equal to or greater than the level defined as “good” (score = 2). The item that showed the highest level of agreement in the first round was the follow-up section, with a mean value of 2.75 ± 0.62. The correlation coefficient, Cronbach’s alpha (Cα), was 0.75. In the second round, for both the CT SR report and the oncologist request template, all elements received “excellent” ratings. During the inter-society agreement, six AIOM members assessed the CT SR model developed by SIRM, while six SIRM members evaluated the CT requesting model proposed by AIOM. In this single Delphi round, all participants assigned the maximum score (3) to every item across all sections. Conclusions The inter-society collaboration between AIOM and SIRM is a milestone in improving communication between radiologists and oncologists. The CT request and reporting documents meet the needs of quality care even outside of referral centers, and although do not represent an obligation, they can facilitate understanding between the different categories of professionals involved in patient management.

12 May 2026 in Livers
Verified
Journal Article
Open access
PDF file
ASAlessandro Serafini
Alessandro Serafini
CGClara Gaetani
Clara Gaetani
LBLaura Bergamasco
Laura Bergamasco
SCStefano Cirillo
Stefano Cirillo
TGTERESA MARIA GALLO
TERESA MARIA GALLO
RFRiccardo Faletti
Riccardo Faletti
Background: Neuroendocrine neoplasms are frequently diagnosed after the detection of liver metastases, often when the primary tumor remains occult. Accurate non-invasive differentiation of neuroendocrine liver metastases (NELMs) from other focal hepatic lesions is therefore crucial. This study aimed to characterize the magnetic resonance imaging (MRI) features of NELMs using hepatocyte-specific contrast agents and to identify a potential radiologic “signature” that may suggest a neuroendocrine origin. Methods: This retrospective study included three cohorts: patients with histologically confirmed NELMs (n = 51; 146 lesions), patients with colorectal cancer liver metastases (n = 18; 46 lesions), and patients with benign hepatic hemangiomas (n = 28; 51 lesions). All subjects underwent standardized liver MRI with Gd-EOB-DTPA. Lesions were evaluated for size, diffusion-weighted imaging characteristics, apparent diffusion coefficient values, arterial-phase enhancement, T2-weighted signal, hepatobiliary-phase appearance, and hemorrhagic components. Statistical analyses included univariate and multivariate testing and receiver operating characteristic curve analysis. Results: NELMs commonly demonstrated arterial hyperenhancement, diffusion restriction, and variable T2 and hepatobiliary-phase signal heterogeneity. Compared with colorectal metastases and hemangiomas, NELMs showed distinctive patterns, particularly higher rates of hepatobiliary-phase heterogeneity and arterial enhancement. Lesion size, ADC metrics, T2 heterogeneity, and hemorrhage were significant discriminators. Conclusions: Hepatocyte-specific MRI enables identification of characteristic imaging features of NELMs. An integrated assessment of morphologic, diffusion, and hepatobiliary-phase findings may facilitate early recognition of neuroendocrine metastases, even when the primary tumor is unknown, improving diagnostic confidence and clinical management.